Cingulate Inc (CING)

Currency in USD
6.210
+0.370(+6.34%)
Closed·
6.200-0.010(-0.16%)
·

Cingulate Inc Company Profile

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.

Contact Information

Address
1901 West 47th Place, Kansas City, 66205, United States
Phone
913 942 2300

Top Executives

Name
Title
Since
Age
John A. RobertsIndependent Chairman of the Board202567
Shane J. SchafferCo-Founder, CEO & Director202551
Bryan Jay LawrenceIndependent Director202460
Jeffrey S. ErvinIndependent Director202448
Jeff HargrovesIndependent Director202659
Peter J. WerthDirector201887
Ann ChildressMember of Scientific Advisory Board--
Brian D. BarashMember of Scientific Advisory Board--
Andrew J. CutlerMember of Scientific Advisory Board--
Laurence L. GreenhillMember of Scientific Advisory Board--
John S. MarkowitzMember of Scientific Advisory Board--
Dinohra Munoz-SilvaMember of Scientific Advisory Board--
Jeffrey NewcornMember of Scientific Advisory Board--
Declan QuinnMember of Scientific Advisory Board--
Sharon B. WigalMember of Scientific Advisory Board--
Alice MaoMember of Scientific Advisory Board--
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.